Cargando…
Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: A phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy
BACKGROUND: In recent years, preoperative volume reduction of locally advanced breast cancers, resulting in higher rates of breast-conserving surgery (BCS), has become increasingly important also in postmenopausal women. Clinical interest has come to center on the third-generation nonsteroidal aroma...
Autores principales: | Krainick-Strobel, Ute E, Lichtenegger, Werner, Wallwiener, Diethelm, Tulusan, Augustinus H, Jänicke, Fritz, Bastert, Gunther, Kiesel, Ludwig, Wackwitz, Birgit, Paepke, Stefan |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2270851/ https://www.ncbi.nlm.nih.gov/pubmed/18302747 http://dx.doi.org/10.1186/1471-2407-8-62 |
Ejemplares similares
-
Vacuum-assisted breast biopsy: A comparison of 11-gauge and 8-gauge needles in benign breast disease
por: Hahn, Markus, et al.
Publicado: (2008) -
The impact of rehabilitation sport on breast cancer-related lymphoedema and quality of life
por: Boeer, Bettina, et al.
Publicado: (2022) -
FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients
por: Fasching, Peter A, et al.
Publicado: (2014) -
Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98
por: Koeberle, Dieter, et al.
Publicado: (2007) -
Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98
por: Koeberle, Dieter, et al.
Publicado: (2007)